Which Country Is Ibrance (Palbociclib) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Ibrance (palbociclib) is a CDK4/6 inhibitor taken as 75 mg, 100 mg or 125 mg capsules or tablets once daily for 21 consecutive days followed by a 7-day break, in combination with an aromatase inhibitor or with fulvestrant, for HR-positive, HER2-negative advanced or metastatic breast cancer. Because it is a self-administered oral medicine taken at home on a cyclical schedule, it moves through retail and specialty pharmacy dispensing rather than hospital infusion suites, which places it on national outpatient reimbursement lists and community pharmacy price schedules rather than inside hospital tender procurement — a genuinely different pricing pathway from infused breast-cancer therapies.

Within the CDK4/6 inhibitor class, Ibrance competes with ribociclib (Kisqali) and abemaciclib (Verzenios), and the extent of that competition varies by market depending on which of the three are reimbursed and on what terms; where all three compete for the same formulary listing, negotiated prices tend to be pushed lower than in markets where only one is available. Palbociclib itself has begun facing generic and biosimilar-style competition in some jurisdictions as patent protections lapse at different times across regions, which is a further factor shaping how its published price compares from one country to the next.

In Türkiye, TİTCK applies external reference pricing to Ibrance as it does to other oral oncology products: the published price tracks the lowest ex-factory price across a defined basket of EU reference countries, converted using the fixed "pharmaceutical euro" (Dönemsel Avro Değeri) rather than the live market rate, as published on the TİTCK price list. Germany's AMNOG framework permits manufacturer-set free pricing for the first months after launch, followed by a negotiated price backdated to month seven. NICE evaluates Ibrance against its cost-per-QALY threshold, raised from the historical £20,000–£30,000 band to £25,000–£35,000, announced 1 December 2025 and effective from April 2026 (see NICE).

The United States lacks an equivalent government reference system for a drug like Ibrance: list prices are set largely freely by Pfizer at launch and then negotiated privately with pharmacy benefit managers and insurers, so the headline list price can diverge sharply from what an insured patient actually pays out of pocket. Because Ibrance moves through retail pharmacy rather than hospital procurement, manufacturer patient-assistance programmes and specialty-pharmacy formulary placement play a larger role in real-world cost than the confidential tender discounts typical of infused biologics. For the structural reasons behind Türkiye's published prices, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Ibrance I'm being offered genuine?

Ibrance is the subject of a real, documented WHO Medical Product Alert: WHO Medical Product Alert 7/2025 concerns falsified Ibrance identified in the supply chain. Anyone sourcing Ibrance outside a licensed retail or specialty pharmacy should check the current WHO alert tracker and verify the pack coding described in that alert before the medicine is dispensed or taken.

Because Ibrance is dispensed as capsules or tablets in a carton with blister strips, verification depends on checking the outer carton, the printed batch and expiry codes, and the tablet or capsule appearance before the blister is opened — a loose strip separated from its original carton cannot be reliably checked against WHO Alert 7/2025 or any other batch-level record.

• Check the current listing on our WHO falsified medicine alerts tracker for WHO Medical Product Alert 7/2025 and compare the affected batch and packaging details against the pack you have been offered.
• Check that the outer carton is intact and shows no evidence of re-sealing, re-taping or having been opened and closed before dispensing.
• Confirm the capsule or tablet's imprint, colour and size match the Pfizer product information leaflet for the strength dispensed.
• Match the batch number and expiry date printed on the outer carton against those printed on the blister foil inside — any mismatch is a hard stop.
• Scan the carton's GS1 DataMatrix and confirm it decodes to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch).
• If sourced in Türkiye, confirm the karekod is registered on the national İlaç Takip Sistemi (İTS) track-and-trace system at its.saglik.gov.tr before it is dispensed.
• Never accept loose capsules or tablets sold without their original carton and blister, and review our guide to checking that a medicine is genuine before dispensing.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Targeted oral therapies

Related high-cost medicines